Endo: Coffee does not impair the bioavailability of LT4 . solution

FRIDAY, June 17, 2022 (HealthDay News) — The bioavailability is equivalent to a single oral dose of levothyroxine sodium (LT4) solution taken five minutes before coffee or under fasting conditions, according to a study presented at the Endocrine Society’s annual meeting. , which was held from June 11 to 14 in Atlanta.

Chris Washington, MD, of Vertice Pharma in Berkeley Heights, New Jersey, and colleagues conducted a bioavailability study to evaluate the rate and extent of absorption of LT4 oral solution administered with coffee compared to administration under fasting conditions in 40 healthy adults. In a crossover study of two periods, two treatments, sequential. In each study period, a single 600 mcg oral dose of LT4 solution was administered five minutes before drinking 8 ounces of American coffee (without milk or sweeteners) or under fasting conditions. For 48 h after drug administration, blood samples were collected for total T4. 40 days washing period separate from treatment periods.

The researchers found that there were no serious adverse events or discontinuation due to adverse events. For baseline-adjusted LT4, the LT4 geometric solution was the mean ratio for the area under the receiver operating characteristic curve from 0 to 48 hours and the maximum serum concentrations were 93.98 percent and 95.99 percent, respectively. The corresponding 90 percent confidence intervals are within the FDA’s range of acceptance for bioequivalence.

“The results showed that absorption of levothyroxine sodium oral solution was not affected by coffee consumption, providing patients and providers with more flexibility in dosing,” Washington said in a statement.

This research was performed by Vertice Pharma, the manufacturer of the oral levothyroxine sodium solution used in the study.

more information

Copyright © 2020 HealthDay. All rights reserved.

Leave a Reply

Your email address will not be published.